Mapp Biopharmaceutical was founded in 2003 to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.
As Mapp's products transition to clinical evaluation, licenses are transferred to Mapp's commercialization partner, LeafBio.
June 10, 2015 - Mapp signs contract with Public Health Agency of Canada
February 27, 2015 - Mapp Bio Clinical Trials Press Release
February 6, 2015 - LeafBio, Inc. submitted an Investigational New Drug (IND) application for clinical evaluation of ZMapp™ to the Food and Drug Administration (FDA) on February 3, 2015.
October 10, 2014 - Status Update on ZMapp™
Mapp Biopharmaceutical, Inc.
6160 Lusk Blvd. # C105
San Diego, CA 92121
phone: 858 625 0335
fax: 800 372 2176
|�2012 Mapp Biopharmaceutical, Inc. All rights reserved.|